Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$13.19M
• Dividend Yield: N/A
• Average Volume (3M): 36.09K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: 95.76%
• EPS Growth: 22.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 131,886,760
• 10 Day Avg. Volume: 35,351
• 30 Day Avg. Volume: 36,089
• PEG Ratio: -0.38
• Price to Book (P/B): -5.82
• Price to Sales (P/S): 18.01
• P/FCF Ratio: -8.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.10 ▼(-31.43% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is mainly held down by weak financial performance—large ongoing losses, negative equity, and continued cash burn—indicating elevated funding and execution risk. Technicals also reflect a clear downtrend despite oversold conditions. Valuation provides limited support due to negative earnings and no indicated dividend yield.

Positive Factors

Proprietary oral fast-dissolve delivery platform

Rapid Dose’s proprietary quick-dissolve oral film technology represents a durable product differentiation and enabling capability. It supports formulation partnerships, licensing and contract-manufacturing opportunities across pharma and nutraceuticals, creating multiple non‑dilutive revenue paths and switching costs for customers.

Revenue growth and improving commercial traction

Revenue growth, though from a small base, has been positive and the income statement notes revenues have generally improved since 2023. This suggests early commercial traction for the core platform and partner formulations, supporting a scalable revenue runway if the company converts more partnerships into repeat business.

Free cash flow showing improvement versus prior period

An improving free cash flow trend signals operational progress and potential greater efficiency in working capital or cost structure. If sustained, this reduces reliance on external funding, increases execution credibility for management, and provides a firmer base to invest in commercialization and R&D.

Negative Factors

Negative shareholders' equity and elevated leverage

The company’s deficit equity position paired with notable debt materially weakens financial flexibility. This structural balance-sheet weakness raises refinancing and solvency risk, constrains strategic options, and increases the probability that future capital raises will be required, diluting existing stakeholders or shifting control.

Ongoing cash burn and negative operating cash flow

Persistently negative operating and free cash flow indicate the business is not self-funding and depends on external capital. Over a multi‑month horizon this increases execution risk, can force dilutive financings or debt, and limits ability to invest consistently in commercial scale-up or R&D without raising new capital.

Severe operating and net margin losses

Very large negative EBIT and net margins relative to revenue reflect structural profitability challenges. Without material margin expansion or significant revenue scale, losses will persist, undermining long‑term viability and making it difficult to demonstrate a path to sustainable profitability to partners or investors.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

How the Company Makes Money

null

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Small TTM revenue base ($2.78M) with modest growth (+5.9%), but profitability is severely negative (EBIT margin ~-111%, net margin ~-157%). Balance sheet risk is elevated with negative shareholders’ equity (~-$6.65M TTM) and meaningful debt (~$8.28M TTM), and cash flow remains negative (TTM operating cash flow ~-$0.91M; free cash flow ~-$3.46M), indicating continued cash burn and funding pressure.

Income Statement

TTM (Trailing-Twelve-Months) revenue is small ($2.78M) with modest growth (+5.9%), but profitability remains very weak: gross margin is ~30% while operating results are deeply negative (EBIT margin ~-111%) and the company is still reporting large net losses (net margin ~-157%). Annual results show revenues have generally improved since 2023, but losses have persisted every year and remain sizable relative to sales, highlighting an ongoing challenge to scale profitably.

Balance Sheet

The balance sheet is strained, with negative shareholders’ equity in the most recent periods (TTM equity about -$6.65M) alongside meaningful debt (TTM total debt about $8.28M). Total assets are relatively low (~$3.79M TTM), and the combination of rising leverage and a deficit equity position increases financial risk and reduces flexibility, particularly if additional funding is needed.

Cash Flow

Cash generation remains weak with negative operating cash flow in TTM (about -$0.91M) and materially negative free cash flow (about -$3.46M), indicating ongoing cash burn. While free cash flow improved versus the prior period (positive growth rate), the company is still not self-funding operations, and the gap between cash outflows and profitability suggests continued reliance on external capital.

Breakdown	TTM	May 2024	May 2023	Nov 2022	Feb 2021	Feb 2020
Income Statement
Total Revenue	2.78M	2.09M	1.02M	718.30K	755.20K	101.50K
Gross Profit	829.37K	1.18M	563.41K	372.40K	699.85K	37.34K
EBITDA	-2.62M	-3.93M	-3.02M	-2.92M	-987.00K	-7.37M
Net Income	-4.37M	-5.40M	-4.31M	-3.81M	-1.80M	-7.96M
Balance Sheet
Total Assets	3.79M	1.63M	1.89M	2.25M	3.83M	4.29M
Cash, Cash Equivalents and Short-Term Investments	109.16K	20.72K	161.06K	27.59K	70.26K	3.47K
Total Debt	8.28M	2.61M	2.45M	1.61M	2.06M	1.22M
Total Liabilities	10.43M	6.84M	5.04M	4.92M	5.41M	4.44M
Stockholders Equity	-6.65M	-5.21M	-3.16M	-2.67M	-1.58M	-147.78K
Cash Flow
Free Cash Flow	-3.46M	-1.15M	-2.29M	-863.92K	-1.63M	-4.26M
Operating Cash Flow	-906.04K	-1.15M	-2.29M	-863.92K	-1.62M	-3.03M
Investing Cash Flow	-2.55M	-5.74K	0.00	0.00	-9.12K	530.46K
Financing Cash Flow	3.49M	1.01M	2.43M	856.53K	1.65M	1.24M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.14, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 33.38 is Neutral, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$15.41M	0.30	―	―	-3.93%	-575.24%
BCT	46 Neutral	C$42.92M	-0.41	-205.87%	―	―	62.01%
HEM	44 Neutral	C$15.62M	-7.36	―	―	―	-24.89%
DOSE	42 Neutral	C$13.19M	-4.62	75.85%	―	95.76%	22.56%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Wins Key Indian Patent for QuickStrip Nicotine Oral Film

Rapid Dose Therapeutics has secured an Indian patent for its QuickStrip nicotine bilayer oral film, developed with Aavishkar Oral Strips, covering a controlled-release, fast-absorbing oral strip and its proprietary manufacturing process. The protection in India, a key consumer market and pharma manufacturing hub, marks a major step in the company’s global IP strategy and supports its push into the fast-growing smoke-free nicotine segment.

The company says the patent, together with broad PCT coverage across up to 158 jurisdictions and its joint ownership structure with Aavishkar, strengthens its negotiating leverage for commercial deals. Management highlighted that this milestone could advance ongoing discussions with a major global nicotine company, potentially enhancing Rapid Dose’s competitive position and value proposition for stakeholders in the expanding modern oral nicotine market.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform

Rapid Dose Therapeutics has provided an update on cannabinoid-focused research and clinical work involving its QuickStrip oral thin film platform. Independent researchers at the University of Regina and the University of Saskatchewan, supported by National Football League grant funding, are studying naturally produced cannabinoids in pain management and neuroprotection for concussion and contact sports.

In a parallel clinical arm launched in Q2 2024, investigators are assessing the bioavailability of cannabidiol delivered via QuickStrip versus traditional oral formats, with more than 60% of participant data already collected and further enrollment continuing into Q2 2026. The company says the ongoing bioavailability and stability studies support the potential of QuickStrip to offer rapid, discreet and efficient cannabinoid delivery, reinforcing its broader applicability across pharmaceutical and wellness applications and potentially enhancing its competitive position in drug delivery solutions.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Lists on U.S. OTCQB to Broaden Investor Access

Rapid Dose Therapeutics Corp., a Canadian biotechnology company specializing in oral thin film drug delivery, is building its QuickStrip portfolio to serve pharmaceutical, nutraceutical and vaccine applications that require rapid and discreet administration. The company continues to list its shares on the Canadian Securities Exchange under the symbol DOSE, maintaining access to its home-market investor base.

The company has begun trading its common shares on the U.S. OTCQB Venture Market under the ticker RDTCF, expanding visibility and access for American healthcare and biotechnology investors. Management says the cross-border listing is intended to enhance liquidity, broaden market participation and support growth, partnerships and commercialization, reinforcing RDT’s positioning within the North American life sciences investment community.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Enters Brazil’s Medical Cannabis Market With QuickStrip Launch

Rapid Dose Therapeutics has launched its co-branded QuickStrip medical cannabis oral thin film in Brazil after securing regulatory approval from Brazil’s health regulator ANVISA for sublingual and buccal administration formats. The product, developed with Entourage Phytolab and distributed via U.S.-based partner Nexxions, positions RDT among the first to offer an oral dissolvable cannabis strip in Brazil’s fast-growing medical cannabis market.

The QuickStrip platform delivers precisely dosed cannabis via rapidly dissolving films designed to treat chronic pain, anxiety, sleep disorders, and neurological symptoms, offering a discreet, non-combustible alternative to oils and capsules. With Brazil’s recent regulatory reforms expanding cultivation permissions, treatment routes, and patient eligibility, and a market projected to grow strongly through 2034, RDT’s early entry and partnerships aim to establish it as a leading provider of consistent, high-quality cannabis therapies in Latin America’s largest healthcare market.

The most recent analyst rating on (TSE:DOSE) stock is a Sell with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The interest payment in shares stems from an amended and restated note financing originally completed in 2023, under which the company extended the maturity of $3.08 million in promissory notes and associated warrants to November 30, 2026; the notes carry an 18% annual interest rate payable in stock at the Canadian Securities Exchange quarter-end closing price, a structure that preserves cash but dilutes existing shareholders while providing continued support from noteholders.

The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.